QR код

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Abstract Gastrointestinal (GI) malignant neoplasms have a high global incidence and treatment prospects for patients with advanced GI tumors are dismal. PD-1/PD-L1 inhibitors emerged as a frontline treatment for several types of cancer. However, the shortcomings of PD-1/PD-L1 inhibitors have been ob...

Повний опис

Збережено в:
Автори: Dongxu Wang, Jianzhen Lin, Xu Yang, Junyu Long, Yi Bai, Xiaobo Yang, Yilei Mao, Xinting Sang, Samuel Seery, Haitao Zhao
Формат: Artigo
Мова:Inglês
Опубліковано: BMC 2019-04-01
Серія:Journal of Hematology & Oncology
Предмети:
Gastrointestinal malignancies
PD-1/PD-L1 blockade
Immune checkpoint inhibitor
Combination immunotherapy
Clinical application
Rationale
Онлайн доступ:http://link.springer.com/article/10.1186/s13045-019-0730-9
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси